Onkologie Urologische Tumoren

En | De
Sie sind hier: Onkologie » Urologische Tumoren 09. Juni 2023
Urologische Tumoren
Erweiterte Suche
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Endokrine Organe
Gynäkologische Tumoren
Urologische Tumoren
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 7704  vorhergehende Seite nächste Seite
   Artikel 1 - 20 / 154079  
Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel.
Modonutti D, Majdalany SE, Butaney M, Davis MJ, Corsi N, Sood A, Trinh QD, Cole AP, Rogers CG, Novara G, Abdollah F.
PMID: 37290911 [PubMed - as supplied by publisher]

Re: The Prevalence of Low-Value Prostate Cancer Screening in Primary Care Clinics: A Study Using the National Ambulatory Medical Care Survey.
J Am Board Fam Med
Takahashi T.
PMID: 37290828 [PubMed - as supplied by publisher]

The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
J Nucl Med
Karimzadeh A, Heck M, Tauber R, Solaris E, Nekolla S, Knorr K, Haller B, D'Alessandria C, Weber WA, Eiber M, Rauscher I.
PMID: 37290796 [PubMed - as supplied by publisher]

Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
J Nucl Med
Hartrampf PE, Mihatsch PW, Seitz AK, Solnes LB, Rowe SP, Pomper MG, Kübler H, Bley TA, Buck AK, Werner RA.
PMID: 37290794 [PubMed - as supplied by publisher]

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK.
PMID: 37290461 [PubMed - as supplied by publisher]

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
J Clin Oncol
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY.
PMID: 37290035 [PubMed - as supplied by publisher]

International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Progresses and Challenges.
Am J Surg Pathol
van der Kwast TH, Bubendorf L, Cheng L.
PMID: 37288838 [PubMed - as supplied by publisher]

Therapeutic Approaches to Penile Cancer: Standards of Care and Recent Developments.
Res Rep Urol
White J, Mason R, Lawen T, Spooner J, Faria KVM, Rahman F, Ramasamy R.
PMID: 37288454 [PubMed]

Preoperative imaging accuracy in size determination of prostate cancer in men undergoing radical prostatectomy for clinically localised disease.
Insights Imaging
Ageeli W, Soha N, Zhang X, Szewcyk-Bieda M, Wilson J, Li C, Nabi G.
PMID: 37286770 [PubMed]

A systematic review on the efficacy of CBT interventions for the mental and sexual health of survivors of prostate cancer.
Sex Med Rev
Pieramico S, Castro R, Aguiar S, Bismarck F, Ferreira D, Carvalho J, Quinta Gomes AL, Nobre P.
PMID: 37286525 [PubMed - as supplied by publisher]

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
BMJ Open
Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R.
PMID: 37286312 [PubMed - in process]

Obesity and renal cell carcinoma: biological mechanisms and perspectives.
Semin Cancer Biol
Venkatesh N, Martini A, McQuade JL, Msaouel P, Hahn AW.
PMID: 37286114 [PubMed - as supplied by publisher]

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K.
PMID: 37285865 [PubMed - as supplied by publisher]

Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.
JCO Precis Oncol
Shankar V, Vijayalakshmi K, Nolley R, Sonn GA, Kao CS, Zhao H, Wen R, Eberlin LS, Tibshirani R, Zare RN, Brooks JD.
PMID: 37285559 [PubMed - in process]

Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards.
PLOS Digit Health
Ural Y, Elter T, Yilmaz Y, Hallek M, Datta RR, Kleinert R, Heidenreich A, Pfister D.
PMID: 37285355 [PubMed]

Biopsy Assessment of Oncologic Control Three Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men with Intermediate Risk Prostate Cancer.
J Urol
Wysock JS, Rapoport E, Hernandez H, Gogaj R, Lepor H.
PMID: 37285232 [PubMed - as supplied by publisher]

A scoring diagnostic system based on biparametric ultrasound features for prostate cancer risk assessment.
Quant Imaging Med Surg
Liu X, Zhou H, Xu X, Li Y, Hong R, Huang K, Shi H, Li F.
PMID: 37284097 [PubMed]

Oligometastasis in Prostate Cancer: Can We Learn from Those "Excluded" from a Phase 2 Trial?
Eur Urol Open Sci
Glicksman RM, Murad V, Santiago AT, Liu Z, Ramotar M, Metser U, Berlin A.
PMID: 37284049 [PubMed]

Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative Data.
Eur Urol Open Sci
Phull M, Begum H, John JB, van Hove M, McGrath J, O'Flynn K, Briggs TWR, Gray WK.
PMID: 37284039 [PubMed]

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.
Front Immunol
Xu C, Zou W, Zhang L, Xu R, Li Y, Feng Y, Zhao R, Wang Y, Liu X, Wang J.
PMID: 37283762 [PubMed - in process]

   Artikel 1 - 20 / 154079    Seite 1 von 7704  vorhergehende Seite nächste Seite

Rect Bottom
Adserver Footer





Haben Sie Ihr Passwort vergessen?


Neu bei My Medline?

Melden Sie sich bei My Medline an!


Mehr über My Medline erfahren

mehr >>


Benutzen Sie englische Suchbegriffe für Ihre Suche in



mehr >>


Sky right 1